After pandemic-related disruptions, will 2021 bring about a renewed spotlight on R&D? A CFO survey says yes
Though venture capital funding swelled during the Covid-19 pandemic and led to a massive boom, other aspects of the health crisis negatively affected the industry, such as restrictions on lab capacities and trial-site interruptions. But, according to a new survey, a majority of life sciences CFOs believe 2021 will be a rebound year.
Nearly seven in 10 CFOs say the new year will bring a redoubled focus on R&D efforts across the industry, per the 2021 BDO Life Sciences CFO Outlook Survey, with 69% forecasting a revenue increase for their companies. Additionally, 81% expect to see profitability rise, while 61% see an economic recovery in the future.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,200+ biopharma pros reading Endpoints daily — and it's free.